NLS BioInvent

BioInvent International has entered into a second clinical trial collaboration and supply agreement with MSD. The two companies will evaluate the combination of one of BioInvent’s anti-TNFR2 antibodies, BI-1808, and MSD’s anti-PD-1 therapy, KEYTRUDA in a Phase 1/2a clinical trial for patients with lung cancer and ovarian cancer. “We are very pleased we have reached […]

The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808. “FDA approval of the Phase I/IIa study of BI-1808 is another important milestone for BioInvent as we continue to broaden our exciting pipeline of anti-cancer antibodies. TNFR2 is increasingly […]

The company plans to in particular use the funds to prepare a clinical trial of their anti-FcγRIIB antibody BI-1206 for the treatment of Non-Hodgkin’s Lymphoma. The Board of Directors of BioInvent International has resolved to issue 19,095,000 shares in a directed share issue to international and Swedish institutional investors, where 2,834,399 New Shares are issued […]

BioInvent International has restructured a clinical development agreement with Cancer Research UK (CRUK) for its anti-FcγRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces BioInvent’s obligations to CRUK, which provides BioInvent with more flexibility to carry out development and partnering activities with BI-1206. It follows BioInvent’s exclusive licensing agreement […]

Cantargia and BioInvent International have announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. CAN10 is fully humanized monoclonal antibody targeting IL1RAP. CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique […]

BioInvent International and CASI Pharmaceuticals, a U.S. biopharmaceutical company with an established clinical development and commercial infrastructure in China, have entered into an exclusive licensing agreement for the development and commercialization of novel anti-FcγRIIB antibody, BI-1206, in mainland China, Taiwan, Hong Kong and Macau. “BioInvent will receive a $5 million upfront payment and is eligible […]